Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
- Trial name
- NCT06274801
- Testing
- Seralutinib, Gereic Dry Powder Inhaler
- Where
- 120 sites in United States, Argentina and 28 more
- Volunteers
- 330 people
- Sponsor
- Gossamer Bio USA, Inc.
Pulmonary Arterial Hypertension
Absorption, Distribution, Metabolism and Excretion of BIA 5-1058
the purpose of this study is: to determine the rate and routes of excretion of BIA 5-1058 and the mass balance in urine, feces and exhaled air, after a single oral dose of 400 mg 14C labeled BIA 5 1058 containing 3.7…
- Trial name
- ADME (NCT04991181)
- Testing
- 400 mg BIA 5-1058
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH
Pulmonary arterial hypertension (PAH) is progressive life limiting disease with a median survival of less than 3 years without treatment.
- Trial name
- RESPIRE (NCT03841344)
- Testing
- MRI
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Pulmonary Arterial Hypertension
Central China Congenital Heart Disease Associated Pulmonary Arterial Hypertension Cohort Study
The study will recruit and follow up patients for five years patients newly diagnosed with congenital heart disease associated pulmonary arterial hypertension(CHD-PAH) from the investigator's hospital.
- Trial name
- CHD-PAHCS (NCT03977428)
- Testing
- standard of care
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Pulmonary Arterial Hypertension
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
In the present study, the investigators want to investigate the prevalence of BMPR-2 gene mutations in the Korean PAH patients (Step-I) and to test that the PAH patients treated with iloprost inhalation solution (Ventavis®) would…
- Trial name
- PILGRIM (NCT01054105)
- Testing
- Iloprost
- Where
- 6 sites in South Korea
- Volunteers
- 73 people
- Sponsor
- Gachon University Gil Medical Center
Takayasu Arteritis, Pulmonary Artery Hypertension
Pulmonary Artery Involvement in Takayasu's Arteritis
The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of…
- Trial name
- NCT03189602
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Pulmonary Arterial Hypertension
The Effect of Adding Exercise Training to Optimal Therapy in PAH
Exercise capacity (EC) is limited in pulmonary arterial hypertension (PAH) by impaired right ventricular (RV) function and inability to increase stroke volume (SV). Disease targeted therapy, increases EC by improving SV.
- Trial name
- NCT02961023
- Testing
- Exercise therapy
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- National Health Service, United Kingdom
Pulmonary Arterial Hypertension
Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain
The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.
- Trial name
- NCT01615627
- Testing
- HypotonicTreprostinil Solution, Eutonic Treprostinil Solution
- Where
- Canada
- Sponsor
- Jewish General Hospital
Pulmonary Artery Hypertension, Chronic Hepatitis c
Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
The purpose of this study is the evaluation of PAH in patients, who are treated with DAA medication for HCV infection.
- Trial name
- NCT04094272
- Testing
- transthoracic doppler-echocardiography (TTE)
- Where
- Switzerland
- Volunteers
- 49 people
- Sponsor
- Kantonsspital Olten
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension
Assessment of the prognostic value of the estimation of plasma volume or its variation in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) after acute right heart…
- Conditions
- Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Acute Right Heart Failure
- Trial name
- NCT05861479
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Pediatric Pulmonary Hypertension
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better…
- Trial name
- MoD (NCT04039464)
- Testing
- Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Johns Hopkins University
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Connective Tissue Diseases, Pulmonary Hypertension
Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients
Measuring the incidence and prevalence of PAH in Egyptian patients with different types of MCD Determination of survival \& the risk factors of mortality.
- Trial name
- NCT02768259
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Hypertension, Pulmonary
Effect of Exercise Training in Patients With Pulmonary Hypertension
Pulmonary Hypertension (PH) is a serious disease with a dismal prognosis when left untreated. Advances in medical therapy have improved survival according to recent registries and systematic reviews, but are associated with high…
- Trial name
- NCT02558582
- Testing
- respiratory and exercise therapy, respiratory and exercise therapy with supplemental oxygen
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- University of Zurich
Interstitial Lung Disease, COPD
Pulmonary Hypertension SOLAR
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI).
- Conditions
- Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
- Trial name
- PH SOLAR (NCT04778046)
- Testing
- Hyperpolarized 129Xe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bastiaan Driehuys
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study
This single-arm, retrospective study aims to evaluate the safety and efficacy of subcutaneous treprostinil as a bridge therapy for lung transplantation in patients with severe pulmonary hypertension (PH).
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Chronic Lung Disease-Associated Pulmonary Hypertension, Lung Transplantation
- Trial name
- NCT06605326
- Testing
- Subcutaneous Treprostinil
- Volunteers
- 46 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Hypertension, Pulmonary
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to…
- Trial name
- PATENT-CHILD (NCT02562235)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 16 sites in Colombia, Germany and 7 more
- Volunteers
- 24 people
- Sponsor
- Bayer
Pulmonary Artery Hypertension
Non-Invasive Measurements of Changes in Pulmonary Artery Pressure in Intensive Care Unit Patients Using Electrical Impedance Tomography - A Feasibility Study
To assess whether changes in electrical impedance - measured using an electrical impedance tomography (EIT) chest belt - can be used to derive changes in pulmonary artery pressure (PAP) in critically ill patients when compared to…
- Trial name
- PAP-EIT (NCT06544148)
- Testing
- Electrical impedance tomography
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Pulmonary Hypertension
The Role of Endothelin in Pulmonary Hypertension
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
- Trial name
- NCT00759408
- Testing
- BQ-123
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Pulmonary Arterial Hypertension
Drug Interaction Between Ritonavir And Sitaxsentan
The study is to assess if sitaxsentan and ritonavir will affect the blood levels of each other when coadministered.
- Trial name
- NCT01251848
- Testing
- Sitaxentan, Ritonavir, Sitaxsentan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer